Unknown PHASE2 INTERVENTIONAL 1-arm NCT04865705

Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer

Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer ,a Single-arm, Phase Ⅱ Clinical Trial

Sponsor: West China Hospital

Conditions Non-small Cell Lung Cancer Stage III

Interventions tislelizumab

Updated 4 times since 2021 Last updated: Apr 28, 2021 Started: Nov 10, 2020 Primary completion: Dec 10, 2021 Completion: Jun 10, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04865705, this PHASE2 trial focuses on Non-small Cell Lung Cancer and Stage III and remains ongoing. Sponsored by West China Hospital, it has been updated 4 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
May 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
May 2021 — May 2023 [monthly]

Active Not Recruiting PHASE2

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

West China Hospital

Data source: West China Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China